VEGFA and Stroke: Furthermore, the safety data from real world population‐based studies17, 18 on intravitreal anti‐VEGFs agents (ranibizumab, aflibercept and bevacizumab) in patients with AMD, found no consistent evidence that intravitreal anti‐VEGF therapy was associated with increased risk of stroke, MI, or death.